Drug intelligence / Profile preview

Qixuekang Oral Liquid

Development stage: Unknown
Lead developer: Yunnan Baiyao
Administration: Oral

Overview

Qixuekang Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed and marketed by Yunnan Baiyao Group. It is composed of several key botanical extracts, typically including *Panax notoginseng* (Sanqi), *Astragalus membranaceus* (Huangqi), *Panax ginseng* (Renshen), and *Angelica sinensis* (Danggui). The product is designed to 'tonify qi and nourish blood,' which in a clinical context translates to improving microcirculation, supporting cardiovascular function, and enhancing vascular health. It is currently undergoing post-marketing redevelopment and clinical research to further validate its efficacy in cardiovascular diseases, with recent studies published in the Journal of Translational Internal Medicine.

Brand names: Qixuekang Oral LiquidQixuekang
Other names: Qixuekang Koufuye

Beyond the preview

Go deeper on Qixuekang Oral Liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qixuekang Oral Liquid.

Explore the full profile